Aloperine induces G2/M phase cell cycle arrest and apoptosis in HCT116 human colon cancer cells

International Journal of Molecular Medicine

Volumn 33, Issue 6, 2014, Pages 1613-1620

  Zhang, Li ^a   Zheng, Yanxin ^a   Deng, Hongzhu ^a   Liang, Lei ^b   Peng, Juan ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c Loudi Central Hospital   (China)

Author keywords

Aloperine; Apoptosis; Cell cycle; Colon cancer; G2 M; HCT116

Indexed keywords

ALOPERINE; ANTIINFLAMMATORY AGENT; CYTISINE; CYTOSINE; HERBACEOUS AGENT; LEHMANNINE; MATRINE; OXYMATRINE; OXYSOPHOCARPINE; PHOSPHATIDYLINOSITOL 3 KINASE; SOPHOCARPINE; SOPHORIDINE; UNCLASSIFIED DRUG; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PIPERIDINE DERIVATIVE; PROTEIN P53;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HUMAN; HUMAN CELL; MTT ASSAY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOPHORA; SOPHORA ALOPECUROIDES; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; CELL CYCLE G2 PHASE; CELL DIVISION; DRUG EFFECTS; GENETICS; METABOLISM;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CYCLIN B1; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; HCT116 CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899575644     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1718     Document Type: Article

References (37)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Ali R, Mirza Z, Ashraf GM, et al: New anticancer agents: recent developments in tumor therapy. Anticancer Res 32: 2999-3005, 2012.
3. Parkinson DR, Arbuck SG, Moore T, Pluda JM and Christian MC: Clinical development of anticancer agents from natural products. Stem Cells 12: 30-43, 1994. (Pubitemid 24045784)
4. Tsukagoshi S: Recent trend on the development of new anticancer drugs. Gan To Kagaku Ryoho 20: 425-431, 1993 (In Japanese).
5. Wang H, Guo S, Qian D, Qian Y and Duan JA: Comparative analysis of quinolizidine alkaloids from different parts of Sophora alopecuroides seeds by UPLC-MS/MS. J Pharm Biomed Anal 67-68: 16-21, 2012.
6. Zhang L, Jiang J and Tan R: Effects of matrine on telomerase activity and cell cycle in K562 cell. Zhonghua Zhong Liu Za Zhi 20: 328-329, 1998 (In Chinese).
7. Zhang LP, Jiang JK, Tam JW, et al: Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res 25: 793-800, 2001. (Pubitemid 32734092)
8. Zhang Z, Wang X, Wu W, et al: Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD). Phytother Res 26: 932-937, 2012.
9. Yuan C, Lu SQ and Yao X: Effects of oxymatrine on the antitumor activity and toxicity of cyclophosphamide in mice. Yao Xue Xue Bao 22: 245-249, 1987.
10. Li XM, Wu YG, Chen SL, Pan DX, Wu JN and Yu YH: Antitumor action of sophoridine. Zhongguo Yao Li Xue Bao 8: 153-158, 1987 (In Chinese).
11. Liang L, Wang XY, Zhang XH, et al: Sophoridine exerts an anticolorectal carcinoma effect through apoptosis induction in vitro and in vivo. Life Sci 91: 1295-1303, 2012.
12. Yuan XY, Liu W, Zhang P, Wang RY and Guo JY: Effects and mechanisms of aloperine on 2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice. Eur J Pharmacol 629: 147-152, 2010.
13. Lin Z, Huang CF, Liu XS and Jiang J: In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens Ait. Basic Clin Pharmacol Toxicol 108: 304-309, 2011.
14. Zhou CC, Gao HB, Sun XB, et al: Anti-inflammatory and anti-allergic action of aloperine. Zhongguo Yao Li Xue Bao 10: 360-365, 1989 (In Chinese).
15. Lin WC and Lin JY: Five bitter compounds display different antiinflammatory effects through modulating cytokine secretion using mouse primary splenocytes in vitro. J Agric Food Chem 59: 184-192, 2011.
16. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
17. Xi S, Gooding WE and Grandis JR: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24: 970-979, 2005. (Pubitemid 40313874)
18. Zhu Z, Li E, Liu Y, et al: Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells. World J Surg Oncol 10: 228, 2012.
19. Lu Y, Zhou J, Xu C, et al: JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 21: 305-314, 2008. (Pubitemid 351591422)
20. Debatin KM and Krammer PH: Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966, 2004.
21. Jin Z and El-Deiry WS: Overview of cell death signaling pathways. Cancer Biol Ther 4: 139-163, 2005. (Pubitemid 41351311)
22. Hu W, Shen T and Wang MH: Cell cycle arrest and apoptosis induced by methyl 3,5-dicaffeoyl quinate in human colon cancer cells: Involvement of the PI3K/Akt and MAP kinase pathways. Chem Biol Interact 194: 48-57, 2011.
23. Itoh K, Hase H, Kojima H, Saotome K, Nishioka K and Kobata T: Central role of mitochondria and p53 in Fas-mediated apoptosis of rheumatoid synovial fibroblasts. Rheumatology (Oxford) 43: 277-285, 2004. (Pubitemid 38313174)
24. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
25. Tsujimoto Y: Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3: 697-707, 1998.
26. Brooks G and La Thangue NB: The cell cycle and drug discovery: the promise and the hope. Drug Discov Today 4: 455-464, 1999. (Pubitemid 29460838)
27. Flatt PM and Pietenpol JA: Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metab Rev 32: 283-305, 2000. (Pubitemid 32001908)
28. Kwak YT, Radaideh SM, Ding L, et al: Cells lacking IKKα show nuclear cyclin D1 overexpression and a neoplastic phenotype: role of IKKα as a tumor suppressor. Mol Cancer Res 9: 341-349, 2011.
29. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998. (Pubitemid 28538613)
30. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994. (Pubitemid 24217131)
31. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8: 409-422, 2004.
32. Lin L, Liu A, Peng Z, et al: STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 71: 7226-7237, 2011.
33. Turkson J and Jove R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626, 2000. (Pubitemid 32197700)
34. Nishimoto A, Kugimiya N, Hosoyama T, Enoki T, Li TS and Hamano K: JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells. Biochem Biophys Res Commun 438: 513-518, 2013.
35. Jia SS, Xi GP, Zhang M, et al: Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells. Oncol Rep 29: 349-354, 2013.
36. Harashima N, Inao T, Imamura R, Okano S, Suda T and Harada M: Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother 61: 667-676, 2012.
37. Liu Y, Mei C, Sun L, et al: The PI3K-Akt pathway regulates calpain 6 expression, proliferation, and apoptosis. Cell Signal 23: 827-836, 2011.